HB0036 / Zhejiang Huahai Pharma - LARVOL DELTA

Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. (PubMed, Front Immunol) - "Firstly, we demonstrated that the bispecific antibody (HB0036) for PD-L1 and TIGIT co-blockade induced a greater T-cell proliferative response in vitro compared to the combined administration of the parental antibodies...Lastly, considering the heterogeneity of tumors, we analyzed how the expression patterns of PD-L1 and CD155 influence T cell responses. We also examined the spatial distribution of PD-L1 and CD155, along with related immunological parameters from patient samples, to assess the potential of PD-L1 and TIGIT co-blockade in diverse tumor contexts."

IO biomarker • Journal • Oncology • CD226 • PVR • TIGIT

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting (GlobeNewswire) - "American Oncology Network...is pleased to announce that several research studies, co-authored by AON physicians and leaders, were accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting."

Clinical data • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Non Small Cell Lung Cancer • Oncology • Small Lymphocytic Lymphoma

A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors. (ASCO 2024) - P1/2 | "HB0036 showed an acceptable safety profile and promising anti-tumor activity in advanced solid tumors, which supports further studies to explore the safety and efficacy of HB0036 as a monotherapy and combination with other anti-tumor agents. Based on these data, phase II monotherapy and combination studies are in preparation. Clinical trial information: NCT05417321."

Clinical • Metastases • P1/2 data • PK/PD data • Anemia • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hypertriglyceridemia • Oncology • Sarcoma • Solid Tumor • TIGIT

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.

New P1/2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK